DBVT insider filings
DBV Technologies S.A. — 39 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-31. Screen DBVT transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for DBVT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — DBV Technologies S.A.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-31 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 464 @ $2.70 | EDGAR |
| 2026-02-02 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 534 @ $4.86 | EDGAR |
| 2026-01-14 | 4 | BAKER BROS. ADVISORS LP — Director Baker Bros. Advisors (GP) LLC — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Option exercise (M): 2,299,656 (derivative) @ $0 · Option exercise (M): 25,005,240 (derivative) @ $0 · Option exercise (M): 2,299,656 (derivative) @ $0 · Option exercise (M): 25,005,240 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | EPIC Bpifrance Bpifrance Participations SA Bpifrance SA Bpifrance Investissement S.A.S. CAISSE DES DEPOTS ET CONSIGNATIONS | Sale (S): 2,036,990 @ $4.84 · Sale (S): 40,000 @ $5.28 · Sale (S): 1,292,103 @ $4.19 | EDGAR |
| 2025-11-25 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 6,496 @ $2.88 · Sale (S): 1,624 @ $2.77 · Grant/award (A): 44,000 @ $0 · Grant/award (A): 253,000 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Trapp Kevin Michael — Chief Commercial Officer | Grant/award (A): 55,000 @ $0 · Grant/award (A): 316,250 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Boucinha Virginie — Chief Financial Officer | Grant/award (A): 32,000 @ $0 · Grant/award (A): 192,000 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Tasse Daniel — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 964,000 (derivative) @ $0 | EDGAR |
| 2025-07-31 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 464 @ $2.22 | EDGAR |
| 2025-05-27 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 397 @ $1.84 | EDGAR |
| 2025-03-31 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner 667, L.P. — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 2,299,656 (derivative) · Grant/award (A): 25,005,240 (derivative) · Grant/award (A): 2,299,656 (derivative) · Grant/award (A): 25,005,240 (derivative) | EDGAR |
| 2025-01-31 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 600 @ $0.85 | EDGAR |
| 2024-12-05 | 4 | Tasse Daniel — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 813,200 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 342 @ $0.53 · Sale (S): 565 @ $0.57 | EDGAR |
| 2024-11-25 | 4 | Mohideen Pharis — Chief Medical Officer | Grant/award (A): 35,000 @ $0 · Sale (S): 2,350 @ $0.54 · Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Boucinha Virginie — Chief Financial Officer | Grant/award (A): 19,000 @ $0 · Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2024-07-31 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 1,785 @ $0.98 | EDGAR |
| 2024-05-29 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 382 @ $1.38 · Sale (S): 660 @ $1.36 | EDGAR |
| 2024-03-11 | 4 | Tasse Daniel — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 17,094 @ $0.83 | EDGAR |
| 2024-02-08 | 4 | Ndu Adora — Director | Purchase (P): 1,825 @ $0.89 | EDGAR |
| 2023-12-19 | 4 | Mohideen Pharis — Chief Medical Officer | Sale (S): 2,245 @ $1.74 | EDGAR |
| 2023-11-22 | 4 | Boucinha Virginie — Chief Financial Officer | Grant/award (A): 19,000 @ $0 · Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Mohideen Pharis — Chief Medical Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Tasse Daniel — Chief Executive Officer, Director | Grant/award (A): 806,672 (derivative) @ $0 | EDGAR |
| 2023-08-28 | 4 | MORRIS TIMOTHY E — Director | Purchase (P): 12,000 @ $1.52 | EDGAR |
| 2023-08-14 | 4 | Mohideen Pharis — Chief Medical Officer | Grant/award (A): 10,000 @ $0 · Grant/award (A): 17,500 @ $0 · Sale (S): 1,792 @ $2.88 · Sale (S): 469 @ $3.54 · Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Robitaille Sebastien — Chief Financial Officer | Grant/award (A): 8,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Tasse Daniel — Chief Executive Officer, Director | Grant/award (A): 764,386 (derivative) @ $0 | EDGAR |
| 2023-08-03 | 4 | SOLAND DANIEL B — Director | Purchase (P): 15,000 @ $1.62 | EDGAR |
| 2022-06-13 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner BAKER JULIAN — Director, 10% owner BAKER FELIX — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner | Grant/award (A): 1,252,432 · Grant/award (A): 10,622,568 · Grant/award (A): 1,383,352 (derivative) · Grant/award (A): 11,732,979 (derivative) | EDGAR |
| 2021-11-24 | 4 | Mohideen Pharis — Chief Medical Officer | Grant/award (A): 8,700 @ $0 · Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2021-11-24 | 4 | Robitaille Sebastien — Chief Financial Officer | Grant/award (A): 5,000 @ $0 · Grant/award (A): 51,000 (derivative) @ $0 | EDGAR |
| 2021-11-24 | 4 | Tasse Daniel — Chief Executive Officer, Director | Grant/award (A): 274,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Ndu Adora — Director | Purchase (P): 6,837 (derivative) @ $7.12 | EDGAR |
| 2021-06-11 | 4 | Monges Viviane — Director | Purchase (P): 5,000 (derivative) @ $7.12 | EDGAR |
| 2021-06-11 | 4 | Rao Madduri Ravin — Director | Purchase (P): 6,837 (derivative) @ $7.12 | EDGAR |
| 2021-06-11 | 4 | SOLAND DANIEL B — Director | Purchase (P): 6,837 (derivative) @ $7.12 | EDGAR |
| 2021-06-11 | 4 | MORRIS TIMOTHY E — Director | Purchase (P): 6,837 (derivative) @ $7.12 | EDGAR |
| 2021-06-11 | 4 | DE ROSEN MICHEL — Director | Purchase (P): 6,837 (derivative) @ $7.12 | EDGAR |
Recent 8-K events — DBV Technologies S.A.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DBVT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs